Osteogenesis imperfecta (OI) is the most prevalent heritable bone fragility disorder in
children. It has been known for three decades that the majority of individuals with OI have …

Osteogenesis imperfecta (OI) is the most common inherited form of bone fragility and
includes a heterogenous group of genetic disorders which most commonly result from …

Despite advances in the diagnosis and treatment of osteogenesis imperfecta, more research
is needed. Bisphosphonate treatment decreases long-bone fracture rates, but such fractures …

Osteogenesis Imperfecta (OI) is characterized by bone fragility. At least seven discrete types
have been described ranging from mild disease to a lethal form. In a large number of cases …

Treatment with bisphosphonates has brought significant clinical improvements for children
and adolescents suffering from moderate to severe forms of osteogenesis imperfecta (OI) …

Osteogenesis imperfecta (OI) is a genetic bone fragility disorder characterized by low bone
mass, skeletal deformity, and variable short stature. OI is predominantly caused by dominant …

Osteogenesis imperfecta (OI), an inherited connective tissue disorder of remarkable clinical
variability, is caused by a quantitative or qualitative defect in collagen synthesis and is …

Bisphosphonates are widely used to treat children with osteogenesis imperfecta (OI), a bone
fragility disorder that is most often caused by mutations in COL1A1 or COL1A2. However, it …

Until recently, medical management of osteogenesis imperfecta, a genetic disorder of
reduced bone mass and frequent fractures, was elusive, and treatment was focused on …

Osteoporosis is an important feature of osteogenesis imperfecta (OI). So far, no effective
medical treatment is available. We treated three boys with severe OI type III and vertebral …